-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
There -X- _ O
is -X- _ O
widespread -X- _ O
interest -X- _ O
in -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
innate -X- _ O
immune -X- _ O
modulators -X- _ O
as -X- _ O
a -X- _ O
defense -X- _ O
strategy -X- _ O
against -X- _ O
infectious -X- _ O
pathogens. -X- _ O
Using -X- _ O
rotavirus -X- _ B-Patient
as -X- _ O
a -X- _ O
model -X- _ O
system -X- _ O
, -X- _ O
we -X- _ O
developed -X- _ O
a -X- _ O
cell-based -X- _ B-Intervention
, -X- _ I-Intervention
moderate-throughput -X- _ I-Intervention
screening -X- _ I-Intervention
( -X- _ I-Intervention
MTS -X- _ I-Intervention
) -X- _ I-Intervention
assay -X- _ I-Intervention
to -X- _ O
identify -X- _ O
compounds -X- _ B-Outcome
that -X- _ I-Outcome
reduce -X- _ I-Outcome
rotavirus -X- _ I-Outcome
infectivity -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
, -X- _ O
toward -X- _ O
a -X- _ O
long-term -X- _ O
goal -X- _ O
of -X- _ O
discovering -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
that -X- _ O
enhance -X- _ O
innate -X- _ O
responses -X- _ O
to -X- _ O
viral -X- _ O
infection -X- _ O
. -X- _ O

RESULTS -X- _ O
: -X- _ O
A -X- _ O
natural -X- _ O
product -X- _ O
library -X- _ O
consisting -X- _ O
of -X- _ O
280 -X- _ O
compounds -X- _ O
was -X- _ O
screened -X- _ O
in -X- _ O
the -X- _ O
assay -X- _ O
and -X- _ O
15 -X- _ O
compounds -X- _ O
that -X- _ O
significantly -X- _ O
reduced -X- _ O
infectivity -X- _ O
without -X- _ O
cytotoxicity -X- _ O
were -X- _ O
identified. -X- _ O
Time -X- _ O
course -X- _ O
analysis -X- _ O
of -X- _ O
four -X- _ O
compounds -X- _ O
with -X- _ O
previously -X- _ O
characterized -X- _ O
effects -X- _ O
on -X- _ O
inflammatory -X- _ O
gene -X- _ O
expression -X- _ O
inhibited -X- _ O
replication -X- _ O
with -X- _ O
pre-treatment -X- _ O
times -X- _ O
as -X- _ O
minimal -X- _ O
as -X- _ O
2 -X- _ O
hours. -X- _ O
Two -X- _ O
of -X- _ O
these -X- _ O
four -X- _ O
compounds -X- _ O
, -X- _ O
α-mangostin -X- _ O
and -X- _ O
18-β-glycyrrhetinic -X- _ O
acid -X- _ O
, -X- _ O
activated -X- _ O
NFκB -X- _ O
and -X- _ O
induced -X- _ O
IL-8 -X- _ O
secretion. -X- _ O
The -X- _ O
assay -X- _ O
is -X- _ O
adaptable -X- _ O
to -X- _ O
other -X- _ O
virus -X- _ O
systems -X- _ O
, -X- _ O
and -X- _ O
amenable -X- _ O
to -X- _ O
full -X- _ O
automation -X- _ O
and -X- _ O
adaptation -X- _ O
to -X- _ O
a -X- _ O
high-throughput -X- _ O
format. -X- _ O
CONCLUSION -X- _ O
: -X- _ O

Identification -X- _ O
of -X- _ O
several -X- _ O
compounds -X- _ O
with -X- _ O
known -X- _ O
effects -X- _ O
on -X- _ O
inflammatory -X- _ O
and -X- _ O
antiviral -X- _ O
gene -X- _ O
expression -X- _ O
that -X- _ O
confer -X- _ O
resistance -X- _ O
to -X- _ O
rotavirus -X- _ O
infection -X- _ O
in -X- _ O
vitro -X- _ O
suggests -X- _ O
the -X- _ O
assay -X- _ O
is -X- _ O
an -X- _ O
appropriate -X- _ O
platform -X- _ O
for -X- _ O
discovery -X- _ O
of -X- _ O
compounds -X- _ O
with -X- _ O
potential -X- _ O
to -X- _ O
amplify -X- _ O
innate -X- _ O
antiviral -X- _ O
responses -X- _ O
. -X- _ O

